Do PPIs Directly Affect Bone Collagen Beyond Calcium Absorption?
This is an opinion piece in Frontiers in Endocrinology, not a trial and not a meta-analysis. It argues that collagen deserves a look as a direct target of proton pump inhibitors, and it builds that argument from laboratory work done in human lung cells and in animal models of lung and skin fibrosis, not in bone-forming cells and not in a clinical study of bone collagen markers. The bone connection it draws is a hypothesis, supported indirectly by fracture epidemiology that does not track with bone mineral density.
Dr. Kumar’s Take
The part of this argument I find hard to dismiss is the mismatch in the fracture data. If PPIs raised fracture risk mainly by blocking calcium absorption, I would expect bone density to fall in long-term users. It largely does not, yet the fracture signal persists, rises with dose and duration, and does not appear with H2 blockers that lower stomach acid just as well. That pattern points somewhere other than calcium. Collagen is a reasonable place to look, because bone is a protein scaffold with mineral laid onto it, and a scaffold can weaken while the mineral density reading stays flat.
I want to be clear about what has and has not been shown. The direct collagen suppression in this paper was demonstrated in lung cells and in fibrosis models, in lung, skin, and liver tissue. Nobody has shown it in osteoblasts here. So I treat this as a mechanism worth testing, not a mechanism established in bone. It does not change what I do at the bedside today, but it does reinforce why I keep asking patients whether they still need the PPI they started years ago.
What the Research Shows
The author summarizes the case in two halves.
The clinical half: PPIs are associated with increased risk of osteoporotic fractures, including hip and vertebral fractures, and a large meta-analysis found a significant association with hip fracture. The FDA added a safety warning label in 2010 covering spine, wrist, and hip fractures. Fracture incidence trends upward with higher dose, greater adherence, and longer duration of PPI use, but not with histamine H2-receptor antagonists, which reduce acid similarly. PPI users are more likely to sustain a fracture and to start osteoporosis medication than non-users. In one study, hormone replacement therapy did not deliver its usual fracture risk reduction when PPIs were taken alongside it. Cohorts comparing long-term PPI users with non-users found no difference in the rate of bone density loss, including in perimenopausal women. Jo et al. reported that PPI use was associated with increased release of calcium and of deoxypyridinoline, a crosslink that gives structural stiffness to the type I collagen in bone.
The laboratory half: in primary cells derived from human lungs, PPIs inhibited gene expression of collagen, including collagen 1A1, and of fibronectin. PPI-treated lung fibroblasts proliferated less and released less collagen. In animals given bleomycin or radiation, both of which drive fibrosis, the PPI esomeprazole significantly reduced collagen accumulation in lung and skin. Other work reported reduced collagen accumulation in the liver. Lung fibrosis patients who happened to be taking PPIs had reduced fibrosis scores on high resolution CT. Mechanistically, the author’s biochemical and immunohistochemical work points to inhibition of DDAH, an enzyme linked to inducible nitric oxide synthase and to inflammatory and fibrotic phenotypes, as a route by which PPIs lower soluble and total collagen. More recent work in human lung cells found PPIs inhibiting gene expression of collagen types 1, 3, and 5.
How This Works (Biological Rationale)
Bone strength depends on mineral content and on the organic matrix, which is mostly type I collagen. That collagen is the framework onto which mineral is deposited, and its crosslinks are what give it stiffness. Deoxypyridinoline is one of those crosslinks, which is why its increased release in PPI users is the observation the author leans on when moving from lung to bone.
The standard explanation for PPI-related fractures runs through acid: less stomach acid, poorer calcium solubility, malabsorption, then hyperparathyroidism, osteoclast activation, and resorption. The author’s objection is that this chain predicts falling bone mineral density, and the cohorts do not show it. The alternative on offer is that PPIs suppress collagen production directly, so matrix quality could degrade while density readings hold steady. The demonstrated suppression is in lung, skin, and liver collagen. Whether the same happens in bone is the open question this piece raises.
Results in Real Numbers
- FDA action: a safety warning label issued in 2010 covering spine, wrist, and hip fractures
- Scale of use: global prescription and over-the-counter PPI sales estimated at about $14 billion, with roughly 113 million prescriptions worldwide
- Collagen genes suppressed in human lung cells: types 1, 3, and 5, including collagen 1A1, plus fibronectin
- Animal fibrosis models: esomeprazole significantly reduced collagen accumulation in lung and skin after bleomycin or radiation
- Fracture risk and bone density: the fracture association is independent of changes in bone mineral density
- Drug class specificity: the dose, adherence, and duration trend appears with PPIs, not with H2 blockers
Safety, Limits, and Caveats
This is an opinion article, so it selects and interprets published work rather than generating new comparative data. The direct collagen findings come from human lung cells, lung fibroblasts, and animal models of lung and skin fibrosis, with supporting liver data. Extending that to the skeleton is an inference, not a measurement. The one human collagen-related signal cited in bone is increased deoxypyridinoline release, from a single study.
The observational fracture data carry the usual limits of observational data, and the author of this piece has a stated interest in the collagen hypothesis, having produced much of the underlying laboratory work.
Practical Takeaways
- The fracture signal with PPIs does not appear to be explained by bone mineral density loss, so a normal DXA scan is not by itself reassurance
- Risk trends with dose, adherence, and duration, which makes the length of therapy the variable most worth revisiting
- H2 blockers lower acid without showing the same fracture trend in the data cited here, which is relevant when an acid-suppressing drug is still needed
- Calcium and vitamin D supplementation targets the mineral pathway, which is the pathway this article argues is not doing the damage
- The collagen mechanism is currently a hypothesis for bone, demonstrated in other tissues, so treat it as a reason to prescribe deliberately rather than a diagnosis to act on
- If a patient is on hormone replacement therapy for bone protection, note the report that concomitant PPI use was associated with loss of that fracture risk reduction
Related Studies and Research
- Osseous Implications of Proton Pump Inhibitor Therapy: Umbrella Review
- Proton Pump Inhibitors and Risk of Fractures: Meta-Analysis of 11 International Studies
- Pharmacology of Proton Pump Inhibitors
- Use of Proton Pump Inhibitors and Risk of Iron Deficiency: Population-Based Study
- Episode 25: The Great GERD Mistake - How Medicine Made Heartburn Worse and How to Fix It
FAQs
Was the collagen effect shown in bone cells?
No. The collagen suppression described here was shown in primary human lung cells and lung fibroblasts, and in animal models of lung and skin fibrosis, with additional reports in liver. Bone is where the author proposes the same mechanism may apply.
Why does the author doubt the calcium absorption explanation?
Because cohorts comparing long-term PPI users with non-users, including perimenopausal women, found no difference in the rate of bone density loss, while the fracture association persists and is independent of bone mineral density changes.
Do H2 blockers show the same pattern?
The article notes that the trend toward more fractures with higher dose, adherence, and duration was seen with PPIs but not with H2-receptor antagonists, even though H2 blockers have similar acid-reducing capability.
Is there any human bone marker evidence in this piece?
Jo et al. reported that PPI use was associated with increased release of calcium and of deoxypyridinoline, the crosslink that stiffens type I collagen in bone. That is the human bone-related collagen signal the article cites.
Does this change bone monitoring in PPI users?
The article raises the question rather than answering it. It argues that a fracture risk independent of bone mineral density means density alone may not capture the problem, but it does not establish a monitoring approach.
Bottom Line
This opinion article proposes that proton pump inhibitors may weaken bone by suppressing collagen directly, rather than by blocking calcium absorption. The supporting evidence for direct collagen suppression comes from human lung cells, lung fibroblasts, and animal fibrosis models, alongside fracture epidemiology showing risk that rises with dose and duration and does not track with bone mineral density. It is a mechanism proposed for bone, not yet demonstrated in bone.
